FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending
Reporting by Noah Smith and Josh Hardman.
The paywall on this article has been temporarily lifted.
This morning, NRx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Abbreviated New Drug Application (ANDA) for its preservative-free ketamine product, which it has previously called KETAFREE1.
KETAFREE is a generic product, hence the ANDA pathway, and is thus approved with the same label as Ketalar, the first ketamine product approved by FDA in 1970. Ketalar’s label describes its use in anaesthesia, and as such KETAFREE is, for now, only on-label for that purpose.
Speaking to Psychedelic Alpha, NRx CEO Jonathan Javitt confirmed that KETAFREE carries the Ketalar label. “The only difference is that it’s preservative-free,” he told us. In other words, it contains no benzethonium chloride (BZT), an antimicrobial preservative used in various medical products, including multidose vials of ketamine.
This time last year, we reported on NRx’s strategy to displace its generic ketamine competitors by:
- bringing a preservative-free ketamine to market; and
- petitioning FDA to remove BZT-containing ketamine products from the market.
Today’s approval completes the first step in that strategy. The second, a citizen petition asking FDA to pull BZT-containing ketamine products from the market, is still with the agency.
Separately, NRx is seeking to bring another preservative-free IV ketamine formulation on-label for depression and suicidality via a new drug application (NDA). That program is dubbed NRX-100, and the NDA would rely largely on existing data, including from NIH-run trials, data licensed from French health authorities, and real-world data collected in the U.S. via Osmind’s platform.
Below, drawing on an interview with Javitt and our reporting, we look at how KETAFREE reached approval, the case NRx has sought to mount against BZT, its claims to be “first” and “American-made”, the commercial picture and, briefly, NRx’s broader plans.
Note: Audio versions of our articles are generated using artificial intelligence, though the voice model is trained on that of our Editor, Josh Hardman.
KETAFREE’s Path Through FDA
KETAFREE’s approval arrives shortly ahead of FDA’s November 10th goal date, but roughly three months later than NRx initially anticipated.
The approval is the company’s first major milestone in its ketamine development efforts, which began nearly three years ago when NRx announced a partnership with Nephron Pharmaceuticals to develop an intravenous formulation of ketamine for suicidal depression.
At that time, though, the agreement’s focus was on developing a depression treatment, not a preservative-free ketamine substitute, and there was no mention of benzethonium chloride anywhere in the announcement. In fact, the company’s preservative-free pitch did not surface until March 2025, when NRx said it would file a generic application and petition FDA to strip BZT from ketamine.
NRx sent its first application to the FDA in June 2025. Then, in September, the company filed a suitability petition asking FDA to allow a 50 mg/5 mL vial, a size Ketalar doesn’t itself come in. FDA’s reply, now in the public record, stated that the agency had already authorised that strength in 2022 based on a petition from Fresenius Kabi, and recommended that NRx withdraw its petition.
The next day, NRx announced that a suitability petition “has been granted for the strength proposed by the Company.” NRx then re-filed its application under the KETAFREE name on September 29 and quietly withdrew its own petition on October 15th.
FDA accepted the company’s re-filed application in December and set a goal date of July 29, 2026. The drug itself appears to have given reviewers little trouble. NRx reported a preliminary bioequivalence finding in March 2026, and only minor labelling and quality comments a month later. In May, NRx placed its first commercial manufacturing order.
However, the company’s vial ultimately delayed its approval. In August, FDA closed its first review cycle with one major item still open: a certification that NRx’s plastic Luer lock vial connects properly to a syringe. In response, NRx supplied an attestation from its manufacturer, and in September FDA downgraded the issue to a minor amendment and reset its goal date to November 10th.
Today, the company announced FDA has approved the ANDA.
How Strong Is the Case Against BZT?
With NRx’s generic Ketalar substitute product now approved, a second part of the company’s apparent strategy is making the case against the inclusion of the preservative in any form of ketamine on the U.S. market.
NRx’s releases have called BZT “a toxic preservative” and “a known neurotoxic substance,” and pitched KETAFREE as part of “current MAHA initiatives” to remove “toxic substances from foods, drugs, and vaccines.” KETAFREE, it said explicitly in a press release, “is designed to align with those priorities.”
Announcing the approval this morning, the company again described BZT as “toxic”, “banned from new drugs”, and not “Generally Recognized as Safe (GRAS)”.
Beyond its public messaging, NRx has asked FDA to act. Its citizen petition, a mechanism through which anyone can ask the agency to take or refrain from an action, reached FDA in September 2025, though it has yet to reach a decision. “That’s still sitting with the agency,” Javitt told us.
We asked Javitt whether FDA, in its approval letter or throughout its review, mentioned anything about the safety of BZT. “They haven’t taken an explicit position,” Javitt told us, before pointing to the agency’s past comments on the preservative.
In its citizen petition, NRx described the preservative as “a known toxic preservative that is not generally recognized as safe and effective” and “a toxic and caustic substance,” part of a class of preservatives “well known to be toxic to epithelial surfaces and to be neurotoxic.” It asked the FDA to “ban all products containing ketamine combined with benzethonium chloride.”
The petition rests largely on how ketamine is used in psychiatry. Approved initially as an anaesthetic, a drug typically given “only once or episodically,” ketamine “is now widely used on a repeated dose basis for the treatment of depression, PTSD, and related disorders”, it reads.
Alongside its citizen petition, NRx filed a toxicology report prepared for its subsidiary, NeuroRx, by Florida-based Biotech Research Group. The report, signed by toxicologist Jerry Bettis, reviews published research, most of it lab and animal studies, and acknowledges that “no formal human toxicology studies evaluating BZT as an injectable excipient have been published.”
Yet the report doesn’t model the types of doses used for psychiatric purposes, which typically see 0.5 mg/kg of ketamine infused over around 40 minutes. Instead, it models single injections at anaesthetic doses and 24-hour continuous infusions of the kind used in intensive care.
The report’s toxicity thresholds come largely from in vitro experiments, some involving 48 to 72 hours of continuous exposure. By its own admission, there are no human pharmacokinetic or toxicity data to anchor those thresholds.
The report also features some inconsistencies. One section puts the BZT delivered by a 24-hour infusion at 28.8 mg; another, along with the executive summary, gives 2.88 mg for the same scenario.
And while the petition calls BZT neurotoxic, a study the report cites multiple times, Brown et al. (2023), found that BZT injected into mice reached their blood but was not detected in their brains. The report doesn’t mention that finding.
None of this shows that BZT is unsafe, or that it is safe; rather, it’s perhaps understudied in humans. Given that, some patients offered the choice may well prefer a vial without it.
When we asked Javitt outright whether patients who have been receiving repeated ketamine infusions for psychiatric disorders have been harmed, he hedged.
“I certainly wouldn’t be confident to say that,” he responded. “I’m not a toxicologist, and probably the levels at which preserved ketamine would exceed the safe human thresholds for BZT are most commonly associated with pain control infusions.”
“It’s not for me to say what levels of ketamine should be used to treat depression,” he went on, “because we don’t have that label.” Depression dosing is often between 0.5 and 1 mg/kg, he noted, “whereas the people who are doing pain control infusions are at a much higher dosage.”
Bladder damage is NRx’s main example of harm. Its petition says interstitial cystitis “is increasingly reported with repeated use of intravenous ketamine” but not with Spravato, which “contains no preservative.” But we noted last year that cystitis among users of illicit ketamine in the UK can’t be explained by BZT, since it mostly involves powdered ketamine, which does not contain the preservative.
Javitt repeated the argument this week. “Ketamine bladder has been reported with injectable ketamine, [but] to the best of anybody’s knowledge, it’s not been a feature of Spravato use,” he told us. Aside from the enantiomeric difference, “the other major difference between the drug ingredients in Spravato and IV ketamine is the preservative.”
When we raised the illicit-use point, Javitt said there are published data showing that, “at certain toxic levels,” ketamine itself “is harmful or believed to be harmful to mitochondrial function in the muscle cells of the bladder.”
In the CEO’s telling, then, ketamine and BZT could both be contributing.
NRx’s telling of the regulatory history of BZT is also open to contention.
Its press release says the preservative is “banned from new drugs”, for example, but it cites FDA’s Inactive Ingredient Database, which lists BZT as an approved excipient with maximum amounts specified by route of administration.
The company also stresses that BZT is not GRAS, a status that comes from food law. Javitt told us that “the regulation says that ingredients of drugs should be GRAS… or demonstrate not to be harmful,” but we were unable to identify this particular rule.
Perhaps unsurprisingly, PH Health, which holds the original FDA approval for Ketalar, had its lawyers oppose the petition, since a ban on BZT-containing ketamine products would force Ketalar, as it is made today, off the market.
PH Health’s filings primarily target NRx’s toxicology report, first pointing out that one of the report’s scenarios assumes an infusion rate four times the highest maintenance rate on Ketalar’s label.
PH also turned NRx’s own argument against it. NRx’s report says BZT “is pharmacologically active and may influence the central or peripheral effects” of ketamine. If so, PH argued, a BZT-free version of Ketalar shouldn’t get the waiver from human bioequivalence studies that injectable generics usually receive; FDA should instead demand “in vivo data establishing bioequivalence.” But FDA has since told NRx it found “no bioequivalence deficiencies” in KETAFREE.
First, and American-Made?
NRx has positioned KETAFREE, which will launch as a 5 mL vial at 10 mg/mL (50 mg) with more sizes to follow, as a first of its kind, and stresses that it is American-made.
As well as playing to the current U.S. health administration’s distaste for preservatives, the company has leaned into the administration’s push to bring drug manufacturing back to the U.S.
Javitt told us the company’s objective was also “to demonstrate that you can return manufacturing of an old generic product to the United States in a commercially sustainable way, because for the United States to depend on an offshore drug supply is just bad for everybody.”
“We are pleased to work with our partners at Nephron Pharmaceuticals in West Columbia, South Carolina, who have helped us prove that sterile, preservative-free injectables can be made in America,” Javitt said in a statement today.
The ketamine itself, however, is not American-made.
When asked whether the drug is made entirely in the U.S., Javitt told us: “The API is not made in the U.S.” The active pharmaceutical ingredient is imported, and only the fill-and-finish happens domestically, despite the petition’s description of a “US manufactured presentation” of ketamine.
But that could change, in time. In October 2025, FDA picked Virginia-based Phlow Corp. for its first round of Commissioner’s National Priority Vouchers, to support domestic production of ketamine API. “If we have the option of moving our API source of supply into the U.S., we would certainly grab that option,” Javitt said, though “reshoring API manufacturers to the U.S. is even harder than reshoring fill-finish.”
NRx’s description of what makes KETAFREE a “first” has narrowed since the company publicly began its development efforts. In December 2025, the company broadly described the product as “the first preservative-free ketamine formulation”, one without the preservatives used in multidose vials. Then, in March 2026, the company’s description of KETAFREE shifted to “the first US-manufactured preservative-free ketamine presentation.”
Today’s release drops “first” altogether, describing the product as “an American-manufactured presentation of ketamine.”
The narrower claim is the one FDA’s records appear to support. NRx’s own toxicology report notes that preservative-free ketamine products are already “marketed internationally”, and in the U.S., Baxter Healthcare appears to have got there first.
In September 2025, more than a year before KETAFREE’s approval, FDA approved a 100 mg/10 mL ketamine syringe from Baxter, the Illinois-based multinational. Its label lists only ketamine, sodium chloride (to make the solution isotonic) and water for injection; no BZT. The preservative-free ketamine syringes are made by Gland Pharma in India.
Whether the product was ever meaningfully available in the U.S. is unclear. FDA’s Orange Book lists it as discontinued, though its drug listing is still active. However, in August 2026, FDA approved a second Baxter ketamine product at 50 mg/5 mL, the same size as KETAFREE, and named it the reference standard for that size.
The newly approved product’s label hasn’t been published, so its formulation isn’t public. Still, it sits on the same FDA application as the preservative-free syringe, at the same concentration, which means that it may well be the same preservative-free product.
Regardless, even Baxter’s initial approval demonstrated that dropping the preservative is a path open to any motivated generic drug maker.
Asked about Baxter’s product, Javitt said: “[We] haven’t seen it, but I’m glad to know that other people are doing preservative-free products.”
Pricing, Supply and NRX-100
At present, without FDA having banned BZT-containing ketamine formulations, it’s not clear what NRx’s commercial moat is.
NRx can’t market KETAFREE as safer than other ketamine, and Javitt confirmed the company did not ask FDA for comparative claims. “Consumers understand what preservative-free means, whether those consumers have a medical degree or not,” he told us, adding: “At low doses, can we say that there’s active harm from the BZT in ketamine? If I were the consumer, I’d prefer not to have it. Nobody’s ever said that it is beneficial to consumers.”
But patients aren’t the ones buying ketamine; hospitals and clinics are.
On price, Javitt suggested NRx will follow the market. A vial of ketamine costs a hospital around “$5 max price at the low end,” he said, “and you have bigger vials, higher strengths get more expensive than that.”
Asked whether NRx plans to charge more, he said the price of old generics, “if it’s not fixed by law, it’s pretty much fixed in the marketplace.” The idea that NRx would charge $1,000 a dose for the hospital product is, he said, “just ludicrous.”
For now, that makes sense. NRx has no exclusivity, and BZT-containing generics remain on the market. But if its citizen petition pushed them out, NRx would have more room to raise prices.
“I don’t think our style is to block other people from anything,” Javitt said when we asked about the company’s ability to defend KETAFREE. “I think our style is to try to advance the market, and we expect that other people will follow if we successfully advance the market.”
But he suggested rivals would struggle to replicate NRx’s product. Traditional glass-vial lines, he said, “can produce, you know, maybe 10,000 units in a single production run,” whereas NRx’s automated blow-fill-seal process makes “much closer to a million doses in a single manufacturing run… all without human hands touching it,” which “gets the manufacturing cost way down.”
Javitt also says NRx, with Nephron, can make ketamine cheaply and at scale. “We are confident that if somebody said, ‘Can you supply the whole U.S.,’ we would be able to do that,” he told us.
NRx could also charge more for NRX-100, its separate preservative-free IV ketamine program, if that product wins a psychiatric label. Aside from offering a more lucrative revenue stream for NRx, that could also help patients and providers.
At present, Spravato, Johnson & Johnson’s esketamine nasal spray, is the only ketamine product on-label for a psychiatric disorder: treatment-resistant depression, and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behaviour. In the U.S. at least, it is often the only form of ketamine that insurers and other payors will reimburse for depression, while patients regularly pay out-of-pocket for off-label generic ketamine, which is many times cheaper.
If NRX-100 won a depression label, it could unlock some reimbursement and offer a cheaper alternative to Spravato. That appeals to many practitioners, who believe ketamine is at least as good as the patented nasal spray, a question a Yale-led, PCORI-funded study is now testing head-to-head.
Javitt didn’t rule out a higher price for an on-label product. “If FDA does allow a label that puts ketamine on label for treating depression, and patients can get insurance reimbursement, will there be a price that works for doctors and patients and insurance companies? I’m sure there will be,” he said.
Some providers are worried about what that price might look like, and that if NRx’s citizen petition pushed other formulations off the market, it could worsen the ketamine shortage and hand NRx something close to a monopoly on generic ketamine.
Javitt dismissed those concerns. Relying on compounding pharmacies is worse, he argued: “there is no supply chain that’s more difficult than relying on compounding pharmacies and giving patients drugs that are not manufactured under an FDA label.” And competition would keep prices in check, he thinks: “this is a sterile injectable product; other people can make it too.”
Pα: The first step of NRx’s commercial strategy is now complete, with FDA approving its preservative-free generic ketamine.
All eyes will now turn to its pending citizen petition, which aims to have FDA remove all BZT-containing ketamine products from the market, and its NRX-100 program, which aims to bring a separate preservative-free formulation on-label for depression.
NRx’s clinical development and commercial strategy seem tailor-made for the priorities of the current U.S. health administration, with our Editor, Josh Hardman, telling the New York Times earlier this month that the company “is certainly seizing the moment”.
From its efforts to publicise concerns around the preservative used in the majority of IV ketamine products through to its focus on manufacturing KETAFREE in the U.S., it has clearly sought to align with government priorities.
Still, with no clear link between BZT and harm in humans, KETAFREE’s active ingredient still made abroad, and its citizen petition pending, NRx’s commercial prospects remain unclear.
And while its generic, preservative-free ketamine approved this week is only on-label for anaesthesia, some clinicians who work with ketamine for psychiatric purposes will likely continue to worry about the potential repercussions on pricing should the company succeed in pushing BZT-containing ketamine off the market.
Multiple providers told Psychedelic Alpha that they struggle to square the company’s language around seeking to end a ketamine shortage in the U.S. with its efforts to knock out the majority of ketamine products that are in circulation. NRx, meanwhile, maintains that it is ready to supply the whole U.S. if such a situation arose, and that it does not intend to block other manufacturers. ∎